Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
出版年份 2016 全文链接
标题
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
作者
关键词
-
出版物
EUROPEAN HEART JOURNAL SUPPLEMENTS
Volume 18, Issue suppl_C, Pages C2-C12
出版商
Oxford University Press (OUP)
发表日期
2017-02-03
DOI
10.1093/eurheartj/suw009
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy
- (2015) Carlos Aguiar et al. ATHEROSCLEROSIS SUPPLEMENTS
- Pathophysiology of diabetic dyslipidaemia: where are we?
- (2015) Bruno Vergès DIABETOLOGIA
- Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
- (2015) Erik S. Stroes et al. EUROPEAN HEART JOURNAL
- Serum uric acid and the risk of cardiovascular and renal disease
- (2015) Claudio Borghi et al. JOURNAL OF HYPERTENSION
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials
- (2015) Giuseppe Derosa et al. PHARMACOLOGICAL RESEARCH
- Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials
- (2015) C. Li et al. Journal of the American Heart Association
- Residual macrovascular risk in 2013: what have we learned?
- (2014) Jean-Charles Fruchart et al. Cardiovascular Diabetology
- An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes
- (2014) J. E. Noonan et al. DIABETES
- The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011
- (2014) K. K. Ray et al. EUROPEAN HEART JOURNAL
- Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease
- (2013) Josef Leebmann et al. CIRCULATION
- Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk
- (2013) Amit V. Khera et al. CIRCULATION
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2013) EUROPEAN HEART JOURNAL
- Fenofibrate and the kidney: an overview
- (2013) Michael S. Kostapanos et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes
- (2013) John J. Albers et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update
- (2013) Ž. Reiner NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Adherence to Statin Treatment and Health Outcomes in an Italian Cohort of Newly Treated Patients: Results From an Administrative Database Analysis
- (2012) Luca Degli Esposti et al. CLINICAL THERAPEUTICS
- Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
- (2012) J. C. Mychaleckyj et al. DIABETES CARE
- Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
- (2012) Anette Varbo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Fenofibrate and Metabolic Syndrome
- (2012) Aldi T. Kraja et al. Endocrine Metabolic & Immune Disorders-Drug Targets
- Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study
- (2011) L. A. Leiter et al. DIABETIC MEDICINE
- Fenofibrate
- (2011) Kate McKeage et al. DRUGS
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
- (2011) M. John Chapman et al. EUROPEAN HEART JOURNAL
- Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada
- (2011) Anselm K Gitt et al. European Journal of Preventive Cardiology
- Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus
- (2010) Peter H. Jones et al. American Journal of Cardiovascular Drugs
- Fenofibrate, Homocysteine and Renal Function
- (2010) Christelle Foucher et al. Current Vascular Pharmacology
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Combination Lipid Therapy in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Combined therapy in the treatment of dyslipidemia
- (2009) Željko Reiner FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies
- (2009) Peter H. Jones et al. Journal of Clinical Lipidology
- Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
- (2009) Kushwin Rajamani et al. LANCET
- Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2008) R. Scott et al. DIABETES CARE
- Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome
- (2008) K. Berneis et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started